Paglalarawan

Cell therapies aims to introduce new, healthy cells into a patient’s body, to replace the diseased or missing ones. Manufacturing them involves collecting a specific set of cells from the blood, modifying them to produce a more vigorous attack on a patient’s cancer cells, and then reinjecting them into the patient. The global cell therapy biomanufacturing market is set to increase by US$ 4.4 bilyon mula sa 2022 sa 2028, representing a compound annual growth rate (CAGR) ng mga 8.8% sa panahon ng pagtataya.

Ang ulat ay nagbibigay ng napapanahong data ng laki ng merkado para sa panahon 2018-2021 at forecast na 2028 covering key market aspects like sales value for cell therapy biomanufacturing. The global cell therapy biomanufacturing market is segmented on the basis of application, at rehiyon. On the basis of application, the global cell therapy biomanufacturing market has been segmented into bone repair, cancer, cardiovascular diseases, neurological disorders, skeletal muscle repair, iba pa ang iba. Kabilang sa mga ito, the skeletal muscle repair segment was accounted for the highest revenue generator in 2021. Sa mga tuntunin ng heograpiya, the global cell therapy biomanufacturing market has been segmented into Asia Pacific, Europa, Hilagang Amerika, MEA (Middle East and Africa), Latin America. North America is estimated to account for the largest share of the global cell therapy biomanufacturing market.

The global cell therapy biomanufacturing market is highly competitive. Tulad ng 2021, the major players in the global cell therapy biomanufacturing market were Bone Therapeutics S.A., Caladrius Biosciences Inc., Iovance Biotherapeutics Inc., Lonza Group AG, Merck KGaA, Novartis AG, Regen BioPharma Inc., Regeneus Ltd., The Bristol-Myers Squibb Company (BMS).

Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the cell therapy biomanufacturing market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

Saklaw ng Ulat

Paglalapat: bone repair, cancer, cardiovascular diseases, neurological disorders, skeletal muscle repair, iba pa ang iba
Rehiyon: Asya Pasipiko, Europa, Hilagang Amerika, MEA (Middle East and Africa), Latin America
Taon na itinuturing: Ang ulat na ito ay sumasaklaw sa panahon 2018 sa 2028

Mga Pangunahing Benepisyo para sa mga Stakeholder

– Get a comprehensive picture of the global cell therapy biomanufacturing market
– Pinpoint ang mga sektor ng paglago at mga trend para sa pamumuhunan

Talaan ng mga Nilalaman

Bahagi 1. Panimula
– Saklaw ng pag aaral
– Panahon ng pag aaral
– Saklaw ng heograpiya
– Paraan ng pananaliksik
Bahagi 2. Cell therapy biomanufacturing market overview
Bahagi 3. Market breakdown by application
– Bone repair
– Cancer
– Cardiovascular diseases
– Neurological disorders
– Skeletal muscle repair
– Ang iba naman
Bahagi 4. Market breakdown by region
– Asya Pasipiko
– Europa
– Hilagang Amerika
– MEA (Middle East and Africa)
– Latin America
Bahagi 5. Mga pangunahing kumpanya
– Bone Therapeutics S.A.
– Caladrius Biosciences, Inc.
– Iovance Biotherapeutics, Inc.
– Lonza Group AG
– Merck KGaA
– Novartis AG
– Regen BioPharma, Inc.
– Regeneus Ltd.
– The Bristol-Myers Squibb Company (BMS)
Tungkol sa StrategyHelix
Pagtanggi